Incannex Healthcare: Disrupting the obstructive sleep apnoea space with IHL-42

Incannex Healthcare (Nasdaq: IXHL, ASX: IHL) is an Australian biotech specialising in the development of treatments for chronic conditions using cannabinoids and psychedelic therapies.

Incannex has 28 clinical programmes in progress and holds one of the world’s largest portfolios of patented cannabinoid drug formulations and psychedelic treatment regimes.

The company’s most advanced clinical asset, IHL-42X, is being developed for the treatment of obstructive sleep apnoea and will see bioavailability and bioequivalence studies roll out in 2023.

Watch Dr Mark Bleackley, Incannex’s chief scientific officer, and Joel Latham, the company’s MD and CEO, being interviewed by Vivienne Parry, to find out more about IHL-42X and Incannex Healthcare’s investment case.